However, of the 4 samples that had reduced or absent dystroglycan in the primary tumour, the most common situation in the larger patient sample of primary only data, there was a significant upregulation of dystroglycan in the secondary metastatic site (Supplementary Table 1, Figure 1IJ). The gene discussed is DAG1; the disease is neoplasm.